Humana (NYSE:HUM) Releases FY 2024 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 16.000- for the period, compared to the consensus EPS estimate of 16.150. The company issued revenue guidance of -.

Humana Stock Up 2.5 %

NYSE:HUM opened at $239.85 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm’s 50-day moving average price is $274.32 and its 200-day moving average price is $322.31. Humana has a 1-year low of $213.31 and a 1-year high of $475.00. The company has a market capitalization of $28.88 billion, a PE ratio of 21.24, a P/E/G ratio of 2.15 and a beta of 0.53.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, equities analysts predict that Humana will post 16.14 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.48%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is currently 31.36%.

Wall Street Analysts Forecast Growth

HUM has been the subject of several recent research reports. Piper Sandler downgraded shares of Humana from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $392.00 to $274.00 in a research note on Thursday, October 3rd. Barclays boosted their target price on shares of Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Leerink Partnrs downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Oppenheimer dropped their target price on Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a report on Thursday, October 3rd. Finally, KeyCorp began coverage on shares of Humana in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $300.50.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.